Profectus BioSciences, Inc. Announces Initiation of Phase I Clinical Trial to Evaluate Safety and Immunogenicity of a Vesicular Stomatitis Virus-vectored HIV-1 Vaccine  
6/1/2011 11:15:48 AM

Profectus BioSciences, Inc., a leader in the development of therapeutic and preventive vaccines against infectious diseases, and the HIV Vaccine Trials Network (HVTN) announced today the initiation of a phase 1 HIV vaccine study involving a recombinant vesicular stomatitis virus (rVSV). VSV, a type of arbovirus that can infect insects and mammals, is commonly used in laboratory settings to study viral evolution. The recombinant version used in this new vaccine study has been weakened, or attenuated, so as not to cause illness in animals or humans.